Specialists Eye Gazyva as a New Option for Lupus Nephritis, but ACR Guidelines Favor Benlysta and Lupkynis for Upfront Use, According to Spherix Global Insights
The ACR’s updated lupus nephritis treatment guidelines emphasize triple therapy regimens anchored by Benlysta or a calcineurin inhibitor, while Gazyva’s potential role in the evolving landscape remains to be established as the field continues to advance. Exton, PA., April 30, 2025 – The American College of Rheumatology’s (ACR) newly updated treatment guidelines for lupus nephritis […]
A Glimpse Inside the CLE Pipeline: What’s Coming Down the Pike?
Dermatologists rely heavily on topical therapies for cutaneous lupus erythematosus (CLE), but are increasingly interested in systemic agents with user-friendly formulations and dermatology-relevant experience such as deucravacitinib (Sotyktu BMS), an oral TYK2 inhibitor currently approved for psoriasis. Familiarity with its mechanism and a favorable safety profile have positioned deucravacitinib as a top contender for future […]
Specialists Set Sights on CLE Pipeline as Unmet Needs Persist and Candidate Pool Expands, According to Spherix Global Insights
Rheumatologists and dermatologists highlight Saphnelo, Sotyktu, and litifilimab as leading candidates to address unmet needs in CLE patients, particularly those with systemic involvement Exton, PA., April 10, 2025 – As treatment approaches for cutaneous lupus erythematosus (CLE) continue to evolve, new data from Spherix Global Insights shed light on how specialists are currently managing the […]
Timely Findings Highlight Increased US Physician Familiarity with IRA Changes Amid Ongoing Reimbursement and Education Concerns, According to Spherix Global Insights
Recently released research reveals key insights into physician perspectives, practice management changes, and expected prescribing changes resulting from recent IRA-driven Medicare changes. EXTON, PA., April 10, 2025 — In 2025, the Inflation Reduction Act (IRA) introduced significant Medicare reforms designed to reduce financial burdens for patients, including a new cap on out-of-pocket (OOP) prescription drug […]
US Rheumatologists Report Heightened Interest in Sotyktu for the Treatment of Psoriatic Arthritis Post Positive Trial Results, According to Spherix Global Insights
While interest in BMS’s pipeline asset is strong, some prescribers are underwhelmed by ACR20 endpoint. EXTON, PA, March 27, 2025 – In late 2024, Bristol Myers Squibb announced positive topline results from its pivotal Phase 3 trials, POETYK PsA-1 and PsA-2, evaluating Sotyktu (deucravacitinib) in adults with active psoriatic arthritis (PsA). Both trials met their […]
Humira Biosimilars Gain Ground as Doctors Adjust and New Therapies Rise
AbbVie’s Humira was the top-selling drug in the world for many years. Now, its sales are eroding as doctors switch to biosimilars and new options enter the market. Immunology physicians are starting to adjust to the new treatment paradigm brought on by the entry of Humira biosimilars, sending sales of AbbVie’s mega-blockbuster down precipitously. But the […]
UCB’s Bimzelx outpacing AbbVie’s Rinvoq, Skyrizi on awareness early in psoriatic arthritis launch: survey
There are signs Bimzelx is affecting the psoriatic arthritis market. UCB’s Bimzelx is firmly on physicians’ radars, with Spherix Global Insights finding that awareness of the drug was tracking ahead of AbbVie’s Rinvoq and Skyrizi three months into its psoriatic arthritis (PsA) launch. Yet, the analysis suggests UCB has work to do to turn awareness into uptake. […]
Early Launch Metrics Indicate UCB’s Bimzelx (bimekizumab) Poised to Disrupt the U.S. Psoriatic Arthritis Market
Rheumatologists’ perceptions of Bimzelx outperform analogue launches of Rinvoq, Skyrizi, and Tremfya in psoriatic arthritis at the three months post-launch mark, according to Spherix Global Insights EXTON, PA, February 13, 2025 – UCB’s Bimzelx (bimekizumab) is making a strong entrance into the U.S. psoriatic arthritis (PsA) market, with early indicators suggesting it could drive a […]
New American College of Rheumatology Guidelines for Lupus Nephritis Recommend Triple Therapy, Highlighting a Shift in Current Treatment Practices, According to Spherix Global Insights
Currently, many lupus nephritis treating rheumatologists and nephrologists delay initiating triple therapy, with a significant portion deferring a triple therapy regimen until an initial failure. EXTON, PA., January 9, 2025 – At the 2024 American College of Rheumatology (ACR) Convergence, the organization unveiled updated guidelines for the screening, treatment, and management of Lupus Nephritis (LN)—the […]
Uptake of Benlysta, Saphnelo signal ‘exciting time’ for ‘lupologists’
Uptake of belimumab continues to outpace the use of anifrolumab among clinicians managing patients with systemic lupus erythematosus, according to a survey conducted by Spherix Global Insights. A top-line data point from the survey suggests that, among patients with SLE currently treated with biologics by the 100 rheumatologist respondents, 62% were receiving belimumab (Benlysta, GlaxoSmithKline) as of […]
